A comparison of live birth rates and cumulative ongoing pregnancy rates between Europe and North America after ovarian stimulation with corifollitropin alfa or recombinant follicle-stimulating hormone

Live birth rates and cumulative pregnancy rates were higher in North America than in Europe after treatment with either corifollitropin alfa or daily recombinant FSH in a double-blind prospective randomized controlled trial.

0
0

Authors

Robert Boostanfar, M.D., Bernadette Mannaerts, M.Sc., Samuel Pang, M.D., Manuel Fernandez-Sanchez, M.D., Han Witjes, Ph.D., Paul Devroey, M.D., Ph.D., Engage Investigators

Vol 97, Issue 6 , Pages 1351-1358

Abstract

Objective:

To compare live birth rates after fresh embryo transfer (ET) and cumulative ongoing pregnancy rates after fresh ET and frozen-thawed (ET) between continents and overall after one treatment cycle with corifollitropin alfa or recombinant FSH.

Design:

Double-blind, multicenter, randomized controlled trial.

Setting:

Fourteen centers in North America (NA); 20 in Europe (EU).

Patient(s):

804 NA patients and 702 EU patients.

Intervention(s):

Patients >60 kg received a single dose of corifollitropin alfa or daily rFSH for the first 7 days of controlled ovarian stimulation.

Main Outcome Measure(s):

Live birth rates.

Result(s):

Within each continent no differences were noted between the two treatment groups; however, between continents, the cumulative ongoing pregnancy rate and live birth rate were considerably higher in NA than in EU. The live birth rate in NA was 39.2% in both treatment groups compared with 31.5% and 28.8% in EU after corifollitropin alfa and rFSH treatment, respectively. Considering the number of embryos transferred, the live birth rate per ET was still higher in NA than in EU (42.7% v.s 36.8% with corifollitropin alfa and 41.6% vs. 30.9% with rFSH). Overall live birth rates after fresh ET were 35.6% and 34.4% (estimated difference 1.1% [95% confidence interval −3.7–5.8]), and the estimated cumulative live birth rates were 43.4% and 41.3% with corifollitropin alfa and rFSH, respectively.

Conclusion(s):

Live birth rates and cumulative pregnancy rates were higher in NA than in EU after treatment with either corifollitropin alfa or daily rFSH; both treatment protocols provided equal success rates.

ClinicalTrials.gov Identifiers:

NCT00703014 and NCT00702273.

Read the full text at: http://www.fertstert.org/article/S0015-0282(12)00272-5/fulltext


Go to the profile of Fertility and Sterility

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. The journal publishes juried original scientific articles in clinical and laboratory research relevant to reproductive endocrinology, urology, andrology, physiology, immunology, genetics, contraception, and menopause. Fertility and Sterility® encourages and supports meaningful basic and clinical research, and facilitates and promotes excellence in professional education, in the field of reproductive medicine.

No comments yet.